Navigation Links
Human C-reactive protein regulates myeloma tumor cell growth and survival
Date:9/10/2007

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatment.

CRP is a protein that is made in the liver and secreted systemically during the process of inflammation in response to the inflammatory cytokine IL-6. The blood level of CRP is elevated in patients with infections, inflammatory diseases, some cardiovascular diseases, and malignancies including multiple myeloma (MM). Dr. Qing Yi and Dr. Jing Yang from the M.D. Anderson Cancer Center and colleagues designed a series of studies to investigate whether human CRP might influence the growth and survival of MM tumor cells.

The researchers found that addition of CRP to cell cultures at levels observed in patients with MM promoted myeloma cell proliferation and protected myeloma cells from chemotherapy-induced apoptosis and apoptosis induced by IL-6 withdrawal. The protective influence of CRP was also validated in a mouse model of myeloma.

The researchers went on to investigate the cell signaling pathways underlying CRP-mediated protection of myeloma cells. They demonstrated that CRP enhanced secretion of IL-6; binds activating Fcg receptors; activates PI3K/Akt, ERK, and NF-kB pathways; and inhibits caspase cascade activation induced by chemotherapy drugs. Further, CRP was shown to synergize with IL-6 in protecting myeloma cells from apoptosis.

These results provide strong evidence that CRP is not just a marker for MM but is a critical regulator of myeloma cell survival. CRP protects myeloma cells from apoptosis induced by chemotherapy drugs and stimulates myeloma cells to secrets more IL-6, which in turn provides additional protection to myeloma from apoptosis and stimulates liver cells to secrete more CRP. Thus, CRP could be a therapeutic target for breaking the vicious circle of myeloma to improve the therapeutic efficacy of currently available treatments, explains Dr. Yi.


'/>"/>

Contact: Nancy Wampler
nwampler@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Controversial deal on public access of the human genome map
4. Man against HIV – new vaccine ready for human trials
5. Scientists plan human cloning clinic in the United States
6. Human gene number increases
7. First human clone is near
8. Water regulation in humans
9. Fossil teeth and human development
10. Scientists found ancient Human Germ Killer
11. New standards for Human Research Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... San Diego ... ) health care reform plan, has announced his candidacy for the 52nd Congressional District ... and shared in America’s Promise. Coming to this country at age eleven after suffering ...
(Date:8/21/2017)... ... August 21, 2017 , ... The Industrial Designers Society of America (IDSA) ... Ceremony and Gala on Aug. 19, 2017 in Atlanta, GA—revealing which 25 designs won ... and rigorous design competitions. See all the winners at http://www.idsa.org/awards/idea/gallery . , “I ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, ... System has assisted multiple clients in successfully passing audits such as Office ... Level 2 (AICPA SOC Level 2), and State Data Use Agreement Audits. ...
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with another ... in a research study that focuses on family interactions when dealing with dietary restrictions. ... of adults who have gluten sensitivities who cohabitate with other adults who may or ...
(Date:8/19/2017)... ... August 18, 2017 , ... Western University of Health Sciences will host a ... University’s new Center for Innovation on Wednesday, September 6, 2017. , The symposium will ... followed by a technology exhibition from 1 to 3 p.m. showcasing virtual reality education ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/3/2017)... SAN DIEGO , Aug. 3, 2017  Opioid ... crippling diseases driving up healthcare costs and threatening outcomes, ... the lab supply and IVD industry that support them, ... health care market researcher said that drugs of abuse, ... vendors and sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology: